Overall, our results indicate that, in part, poziotinib reverses MDR in S1-M1-80 and SW620/Ad300 colon cancer cell by inhibiting the efflux of ABCG2 and ABCB1 substrates, respectively. The gene discussed is ABCB1; the disease is colonic neoplasm.